Skip to main content

Advertisement

SpringerLink
Log in

Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, Japan

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Population-based prostate-specific antigen (PSA) screening is effective for reducing prostate cancer (PCa)-related mortality rates. In this study, we assessed biopsy-proven maximum cancer core length (MCCL) and maximum cancer diameter on magnetic resonance imaging (MRI; MCDM) in prostate biopsy and multiparametric MRI (mp-MRI) by PCa detection.

Methods

We retrospectively assessed 214 male PCa patients and 187 PCa patients with Prostate Imaging Reporting and Data System version 2 (PI-RADS) category 3–5 lesions in pre-biopsy mp-MRI and targeted biopsy characteristics. The mean biopsy-proven MCCL and MCDM were compared among three PSA screening groups, namely the population-based PSA screening (PBS), opportunistic PSA screening (OPS), and symptomatic outpatient PSA examination (SOP) groups.

Results

The median age and PSA value of the 214 participants were 75 years and 7.9 ng/mL, respectively. In the PBS, OPS, and SOP groups, the median ages were 73, 76, and 76 years, respectively (p = 0.046); PSA values were 7.2, 9.5, and 11.5 ng/mL, respectively (p < 0.001); and biopsy-proven MCCL and MCDM were significantly increased to 7, 10, and 14 mm (p < 0.001) and to 11, 15, and 17 mm (p < 0.001), respectively. In the 187 PCa patients with PI-RADS category 3–5 lesions on mp-MRI, MCDM were 11, 14, and 17 mm (p < 0.001), respectively.

Conclusions

The biopsy-proven MCCL and MCDM were significantly smaller in the PBS and OPS groups than in the SOP group, which suggests that PSA screening detected PCa earlier than in symptomatic patients. PSA screening with MRI could objectively lead to earlier diagnosis based on tumor size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Schröder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328. https://doi.org/10.1056/NEJMoa0810084

    Article  PubMed  Google Scholar 

  2. Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725–732. https://doi.org/10.1016/S1470-2045(10)70146-7

    Article  PubMed  PubMed Central  Google Scholar 

  3. Andriole GL, Crawford ED, Grubb RL et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319. https://doi.org/10.1056/NEJMoa0810696

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hamashima C, Nakayama T, Sagawa M et al (2009) The Japanese guideline for prostate cancer screening. Jpn J Clin Oncol 39(6):339–351. https://doi.org/10.1093/jjco/hyp025

    Article  PubMed  Google Scholar 

  5. Association JU (2018) Screening guideline for prostate cancer: medical review, 1st edn. Association JU

    Google Scholar 

  6. Oberaigner W, Siebert U, Horninger W et al (2012) Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 57(1):57–62. https://doi.org/10.1007/s00038-011-0266-4

    Article  PubMed  Google Scholar 

  7. Okihara K, Kitamura K, Okada K et al (2008) Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int J Urol 15(2):156–160. https://doi.org/10.1111/j.1442-2042.2007.01957.x (Discussion 161)

    Article  CAS  PubMed  Google Scholar 

  8. National institute of population and social security research. Population and social security in Japan 2019. http://www.ipss.go.jp/s-info/e/pssj/pssj2019.pdf. Accessed 20 May 2021

  9. Matsugasumi T, Baco E, Palmer S et al (2015) Prostate cancer volume estimation by combining magnetic resonance imaging and targeted biopsy proven cancer core length: correlation with cancer volume. J Urol 194(4):957–965. https://doi.org/10.1016/j.juro.2015.04.075

    Article  PubMed  Google Scholar 

  10. Epstein JI, Amin MB, Reuter VE et al (2017) Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 41(4):e1–e7. https://doi.org/10.1097/PAS.0000000000000820

    Article  PubMed  Google Scholar 

  11. International Union Against Cancer (1997) Urologic tumors: prostate. In: Sobin LH, Wittekind CH (eds) TMN classification of malignant tumors, 5th edn. Wiley, New York, pp 170–173

    Google Scholar 

  12. Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1. Screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003

    Article  PubMed  Google Scholar 

  13. Fenton JJ, Weyrich MS, Durbin S et al (2018) Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA 319(18):1914–1931. https://doi.org/10.1001/jama.2018.3712

    Article  PubMed  Google Scholar 

  14. Gandaglia G, Albers P, Abrahamsson PA et al (2019) Structured population-based prostate-specific antigen screening for prostate cancer: the European association of urology position in 2019. Eur Urol 76(2):142–150. https://doi.org/10.1016/j.eururo.2019.04.033

    Article  PubMed  Google Scholar 

  15. de Rooij M, Hamoen EH, Witjes JA et al (2016) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 70(2):233–245. https://doi.org/10.1016/j.eururo.2015.07.029

    Article  PubMed  Google Scholar 

  16. Cornud F, Khoury G, Bouazza N et al (2014) Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol 191(5):1272–1279. https://doi.org/10.1016/j.juro.2013.12.006

    Article  CAS  PubMed  Google Scholar 

  17. Donati OF, Afaq A, Vargas HA et al (2014) Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score. Clin Cancer Res 20(14):3705–3711. https://doi.org/10.1158/1078-0432.CCR-14-0044

    Article  PubMed  Google Scholar 

  18. Kitagawa Y, Mizokami A, Namiki M (2013) Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening. Prostate Int 1(2):65–68. https://doi.org/10.12954/PI.12017

    Article  PubMed  PubMed Central  Google Scholar 

  19. Tabei T, Taguri M, Sakai N et al (2020) Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening. Prostate 80(11):824–830. https://doi.org/10.1002/pros.23997

    Article  CAS  PubMed  Google Scholar 

  20. Fujimoto H, Nakanishi H, Miki T et al (2011) Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol 18(12):876–881. https://doi.org/10.1111/j.1442-2042.2011.02895.x

    Article  PubMed  Google Scholar 

  21. Kakehi Y, Sugimoto M, Taoka R et al (2017) Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol 24(9):648–666. https://doi.org/10.1111/iju.13380

    Article  PubMed  Google Scholar 

  22. Droz JP, Aapro M, Balducci L et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):e404–e414. https://doi.org/10.1016/S1470-2045(14)70018-X (PMID: 25079103)

    Article  PubMed  Google Scholar 

  23. Morote J, Morin JP, Orsola A et al (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69(3):500–504. https://doi.org/10.1016/j.urology.2006.11.002

    Article  PubMed  Google Scholar 

  24. Oliveira A, Vaz C (2015) The role of sarcopenia in the risk of osteoporotic hip fracture. Clin Rheumatol 34(10):1673–1680. https://doi.org/10.1007/s10067-015-2943-9

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Kyoto Prefectural University of Medicine, 465, Kajiicho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan

    Toru Matsugasumi, Koji Okihara, Masashi Tsujimoto, Yasuhiro Yamada, Atsuko Fujihara, Takumi Shiraishi, Fumiya Hongo & Osamu Ukimura

  2. Department of Urology, North Medical Center, Kyoto Prefectural University of Medicine, 481 Otokoyama, Yosano-cho, Kyoto, 629-2261, Japan

    Toru Matsugasumi, Koji Okihara & Masashi Tsujimoto

  3. Department of Radiology, North Medical Center, Kyoto Prefectural University of Medicine, 481 Otokoyama, Yosano-cho, Kyoto, 629-2261, Japan

    Osamu Sato

  4. Department of Pathology, North Medical Center, Kyoto Prefectural University of Medicine, 481 Otokoyama, Yosano-cho, Kyoto, 629-2261, Japan

    Tetsuya Imura

Authors
  1. Toru Matsugasumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koji Okihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masashi Tsujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Osamu Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuya Imura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuhiro Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsuko Fujihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takumi Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fumiya Hongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Osamu Ukimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Osamu Ukimura.

Ethics declarations

Conflict of interest

None declared.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsugasumi, T., Okihara, K., Tsujimoto, M. et al. Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, Japan. Int J Clin Oncol 26, 2303–2309 (2021). https://doi.org/10.1007/s10147-021-02016-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-021-02016-5

Keywords

Search

Navigation